about
Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelPreventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analysesPrenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analysesA systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescentsWarfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare dataThe functional response of a generalist predatorCost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.Is primary angioplasty cost effective in the UK? Results of a comprehensive decision analysis.Assessing the effectiveness of primary angioplasty compared with thrombolysis and its relationship to time delay: a Bayesian evidence synthesis.Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection.Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison.Multivariate Prediction Equations for HbA1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling.Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial.Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden--with model applications for Denmark, Norway and Finland.Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.Erratum to: Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM).Sensitivity to assumptions in models of generalist predation on a cyclic prey.Cost effectiveness of golimumab for the treatment of active psoriatic arthritis.Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM).The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood ChallengePrimary angioplasty versus thrombolysis for acute ST-elevation myocardial infarction: an economic analysis of the National Infarct Angioplasty project[Indirect comparison and network meta-analyses--new tools for the assessment of evidence on the relative efficacy of drugs]Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsModelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival ModellingConducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors
P50
Q21134108-60F33AA7-3AF5-49B3-8EDA-693A0B0661D2Q24680268-5EDF8362-D81C-4FCE-918B-F0F8A3B172BAQ28237573-5751A2B2-4E4A-4BBF-AE2C-8B95544EABE2Q28248118-866C7902-2316-40E7-A766-94B171052FCFQ30766944-3E7693C4-E2F3-45F1-9900-4A3EC17F9943Q33594274-97AA2D22-FDFF-4315-BB3D-492E76439FB3Q34722577-1DF1632F-9CCB-4CE4-84D4-A01A323E8A5EQ36025741-2FB31637-F734-41A4-98CC-2406B6C6D215Q36025772-FE5C859D-C811-42BD-80B0-F45552E1101AQ36168439-08F00322-B379-412C-ABFF-A421AE4FC437Q38046676-C45CFE74-B44D-4723-BF36-9773A465C8CBQ38908589-0EAC0ED2-9855-4002-BF65-C0C8AEB7C9B5Q39785686-FFD7E987-76BB-4C6B-B96C-F3495D229595Q43269086-15EF7C14-1595-4DD0-B5E2-0F7799456E92Q43695561-53418922-2EF4-48BA-AAA9-8F28C193D2E5Q46716732-02AE73BE-ABF2-4DD2-BA74-462F96D0D3C8Q48230405-A58A9D1B-749E-4BB6-8363-202C1200080EQ50669474-8BA73DA0-B96E-498A-B205-0AE25D98510EQ51166513-0938D3A8-6CB1-44CB-B707-C9CBC5DFE3A3Q51211134-7BCEFEAE-5894-41C4-BD29-2D896A0B0D22Q51441351-89716F1C-F0F1-4A96-A9E3-8D14F806EF72Q51734403-3032BA7C-A10C-42D5-8950-9D004355C611Q58477928-802BBD2E-1BF7-45F2-956D-7B7F29E8C9A1Q61651178-89205CA7-94C1-416D-97ED-5F245DC38048Q84291712-92CE65BF-D125-4DC7-A663-4ED07087D4D8Q89239848-BFD84144-C1B0-4DBB-A550-CA067D56C211Q89239874-24A967B2-6EB6-4BB1-9EDF-F224448E64F8Q91037735-4947B778-E82A-4F4B-AA62-AE537FBE793F
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Christian Asseburg
@ast
Christian Asseburg
@en
Christian Asseburg
@es
Christian Asseburg
@nl
Christian Asseburg
@sl
type
label
Christian Asseburg
@ast
Christian Asseburg
@en
Christian Asseburg
@es
Christian Asseburg
@nl
Christian Asseburg
@sl
prefLabel
Christian Asseburg
@ast
Christian Asseburg
@en
Christian Asseburg
@es
Christian Asseburg
@nl
Christian Asseburg
@sl
P106
P1153
14419819000
P21
P31
P496
0000-0001-7196-3363